海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

休市中 05-15 16:09:04

219.600

-12.000

-5.18%

最高238.800	最低215.200	成交量17.73万
今开229.200	昨收231.600	日振幅10.19%
总市值172.84亿	流通市值172.84亿	总股本7,871万
成交额3,909万	换手率0.23%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":219.6,"timestamp":1778832544008,"preClose":231.6,"halted":0,"volume":177300,"delay":0,"changeRate":-0.05181347150259068,"floatShares":78707270,"shares":78707270,"eps":2.9326657945448,"marketStatus":"休市中","change":-12,"latestTime":"05-15 16:09:04","open":229.2,"high":238.8,"low":215.2,"amount":39089370,"amplitude":0.1019,"askPrice":219.6,"askSize":600,"bidPrice":217,"bidSize":7250,"shortable":0,"etf":0,"ttmEps":2.8636618934966873,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":7,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":231.6,"openAndCloseTimeList":[[1778808600000,1778817600000],[1778821200000,1778832000000]],"volumeRatio":0.7133890200690253,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637/tweets","defaultTab":"tweets","newsList":[{"id":"1178209460","title":"海西新药4月股份变动月报表披露，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1178209460","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178209460?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:48","pubTimestamp":1778147291,"startTime":"0","endTime":"0","summary":"5月7日，福建海西新药创制股份有限公司发布截至2026年4月30日的股份变动月报表。公告显示，公司于报告期内的已发行股本和注册股本均无任何增减变化，股本状况保持稳定。福建海西新药创制股份有限公司在报告期内的普通股H股股份总数维持在78,707,270股，公司注册股本合计人民币78,707,270元，面值每股人民币1元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182854792","title":"异动解读 | 海西新药盘中大涨5.74%，年报业绩超预期叠加券商首次覆盖提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1182854792","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182854792?lang=zh_cn&edition=full","pubTime":"2026-05-05 09:38","pubTimestamp":1777945135,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨5.74%，引起了市场的广泛关注。消息面上，公司近日披露的2025年度报告显示，其营业收入和归母净利润均实现显著增长，业绩表现超出市场预期。与此同时，华源证券首次覆盖该股并给予“买入”评级，指出公司正升级为“仿创一体化”药企，其创新药HXP056为潜在首批口服治疗wAMD/DME/RVO的药物，有望打开中长期估值空间。华源证券在报告中强调，海西新药的战略转型和研发管线进展，特别是HXP056的潜力，是支撑其“买入”评级和未来估值提升的关键因素。市场分析认为，今日的股价反弹反映了投资者对公司基本面利好的重新定价。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172614044","title":"异动解读 | 海西新药盘中大跌8.35%，解禁抛压与高位回落致股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1172614044","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172614044?lang=zh_cn&edition=full","pubTime":"2026-05-04 09:56","pubTimestamp":1777859794,"startTime":"0","endTime":"0","summary":"海西新药(02637)今日盘中大跌8.35%，引起了市场的广泛关注。消息面上，该股此前近一个月内股价实现翻倍，触及历史高点后曾单日暴跌逾25%，虽随后连续反弹，但整体仍处于高位震荡回落格局。此外，该股上市满半年迎来解禁，基石投资者持有198.17万股，占总股本2.52%，短期抛压仍需消化。前期获利盘出逃叠加解禁压力，共同压制股价表现。当前成交额明显萎缩，市场观望情绪浓厚，股价在多重因素影响下持续调整。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632604150","title":"格隆汇个股放量排行榜 | 5月3日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632604150","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632604150?lang=zh_cn&edition=full","pubTime":"2026-05-03 17:30","pubTimestamp":1777800604,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/03173056983654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02676","00133","00719","00259","02516","01211","00880","00148","02408","00220","06821","00019","09990","01458","01347","00168","00178","01765","06938","02655","00189","00363","00709","02489","06110","02687","00981","01429","09903","00659","00501","00780","02583","01643","06979","01833","09927","00909","02579","02276","02637","00568","02595","09999","00800","00650","00815","00558","02656","02443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632158966","title":"格隆汇个股放量排行榜 | 5月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2632158966","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632158966?lang=zh_cn&edition=full","pubTime":"2026-05-01 17:30","pubTimestamp":1777627804,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日天数智芯(09903)、上海实业控股(00363)、网易-S(09999)、永达汽车(03669)、永利澳门(01128)、中国铁建(01186)、中国信达(01359)、力量发展(01277)、中国光大银行(06818)、汽车街(02443)、中国白银集团(00815)、赛力斯(09927)、太古股份公司A(00019)、中信国际电讯(01883)、华星控股(08","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/01173056970876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01458","02637","01833","00815","00568","09999","02579","02583","00501","02516","00880","00133","06110","01765","06821","00709","00719","02489","00148","00259","00178","06938","01347","02443","02676","00650","00168","09990","02408","02656","02655","06979","00800","09903","00981","09927","02687","02276","00220","00363","01643","00189","00659","00909","01211","00780","00019","01429","02595","00558"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2631468969","title":"【券商聚焦】华源证券首予海西新药(02637)“买入”评级 指创新药HXP056有望打开估值空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2631468969","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631468969?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:45","pubTimestamp":1777538722,"startTime":"0","endTime":"0","summary":"报告指，公司正从传统仿制药商业化平台升级为“仿创一体化”药企，仿制药业务提供稳定现金流，创新管线HXP056有望打开中长期估值上限。业务亮点包括：1.创新药HXP056：为潜在首批口服治疗wAMD/DME/RVO的药物，全球尚无已获批的wAMD口服制剂。2025年仿制药收入结构中，海慧通占比50.29%，安必力占比27.94%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZmY0OWUwYjc0ZDYzZDFkYzRkNWJlMTY3NjE5MjUxNjU=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980352","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","161027","06978","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142571820","title":"异动解读 | 海西新药盘中大涨9.54%，股份激励计划与机构看好推动股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1142571820","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142571820?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:38","pubTimestamp":1777513130,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨9.54%，引起了市场的广泛关注。消息面上，公司董事会决议建议采纳H股股份激励计划，旨在建立长效激励机制，将股东、公司及员工利益紧密结合，此举增强了市场对公司未来发展的信心。同时，申万宏源近期首次覆盖该股并给予“买入”评级，目标价298.28港元，指出公司仿制药业务稳健，创新药管线进展积极。此外，该股此前经历了一段回调，此次上涨也包含了技术性反弹的因素。股份激励计划的落地与机构看好其基本面，共同推动了股价的强劲表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144056621","title":"海西新药(02637)2025年收入与利润稳步增长，持续加码研发推进创新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1144056621","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144056621?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:59","pubTimestamp":1777467566,"startTime":"0","endTime":"0","summary":"海西新药于2025年度实现主要经营指标的多重增长。据年报显示，集团期内收入达到5.82亿元人民币，其中15款获国家药品监督管理部门批准上市的仿制药有力支撑业绩。2025年集团净利润为1.77亿元人民币，同比上升30.1%，毛利达4.86亿元人民币，同比增长25.4%，毛利率水平维持在83.4%的较高位置，表现出良好的盈利能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海西新药(02637)2025年收入与利润稳步增长，持续加码研发推进创新药管线","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631520514","title":"海西新药(02637)建议采纳H股股份激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2631520514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631520514?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:49","pubTimestamp":1777466974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药(02637)发布公告，于2026年4月29日，董事会已决议建议采纳一项适用于公司H股的股份激励计划。股份激励计划旨在进一步建立、健全公司的长效激励机制，充分调动核心员工的积极性，有效地将公司股东利益、公司利益及员工个人利益结合在一起，使各方共同推动公司的持续健康发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163511873","title":"异动解读 | 海西新药盘中大涨7.66%，机构看好与创新药进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1163511873","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163511873?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:59","pubTimestamp":1777427999,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨7.66%，引起了市场的广泛关注。消息面上，申万宏源近期首次覆盖海西新药并给予\"买入\"评级，目标价298.28港元。公司仿制药业务已连续5年实现盈利，营业收入达5.82亿元人民币，同比增长25%，净利润1.77亿元，同比增长30%。创新药方面，C019199即将进入III期临床阶段，HXP056有望迎来数据验证。此外，该股前一交易日曾一度跌超25%，由历史高点大幅回落，今日呈现技术性反弹。需关注的是，该股此前上市满半年迎来解禁，基石投资者持有198.17万股，占总股本2.52%，短期抛压仍需消化。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173921670","title":"异动解读 | 海西新药盘中大涨5.06%，券商首次覆盖叠加创新药管线催化推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1173921670","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173921670?lang=zh_cn&edition=full","pubTime":"2026-04-28 09:48","pubTimestamp":1777340905,"startTime":"0","endTime":"0","summary":"海西新药今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，申万宏源近日首次覆盖海西新药并给予“买入”评级，目标价298.28港元。研报指出，公司仿制药业务已连续5年盈利，营业收入达5.82亿元人民币，同比增长25%，净利润1.77亿元，同比增长30%。此外，公司公告新一代原创创新药HXP056口服治疗眼底病I期临床数据显示良好安全性与耐受性，在wAMD患者中观察到眼底形态与视网膜功能初步改善，具有全球重磅大单品潜力；进度最快的C019199即将进入III期临床阶段。券商首次覆盖叠加创新药管线数据验证预期，共同推动了公司股价的强势表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630442356","title":"港股异动丨海西新药大涨近18%创新高，年内已累涨超105%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630442356","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630442356?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:27","pubTimestamp":1777260422,"startTime":"0","endTime":"0","summary":"海西新药盘中一度大涨近18%，最高触及280港元，创下历史新高。该股年内已累计上涨超105%。　　消息面上，海西新药于上月底公布2025年业绩，收益约5.82亿元，同比增长24.79%；净利约1.77亿元，同比增长30.09%。　　另外，申万宏源近期研报首次覆盖海西新药，给予“买入”评级。该行指，在稳定且持续盈利后，公司大力推进创新药研发，进度最快的C019199即将进入III期临床阶段，具有全球重磅大单品潜力的HXP056有望迎来数据验证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260427/32178800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02637","BK1191","VXUS","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151352006","title":"异动解读 | 海西新药盘中大涨14.56%，获券商首次覆盖及创新药管线进展推动","url":"https://stock-news.laohu8.com/highlight/detail?id=1151352006","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151352006?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:51","pubTimestamp":1777254687,"startTime":"0","endTime":"0","summary":"海西新药（02637）今日盘中大涨14.56%，引起了市场的广泛关注。消息面上，申万宏源近日首次覆盖海西新药并给予“买入”评级，目标价298.28港元，指出公司仿制药业务已连续5年盈利，营业收入达5.82亿元人民币，同比增长25%，净利润1.77亿元，同比增长30%。此外，公司公告新一代原创创新药HXP056口服治疗眼底病I期临床数据显示良好安全性与耐受性，在wAMD患者中观察到眼底形态与视网膜功能初步改善，具有全球重磅大单品潜力；进度最快的C019199即将进入III期临床阶段。券商首覆叠加管线数据验证预期，推动股价延续强势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9e8df464b3152108e143b234dfe2216d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629901508","title":"【券商聚焦】申万宏源首予海西新药(02637)“买入”评级 指其大力推进创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2629901508","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629901508?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:42","pubTimestamp":1777012941,"startTime":"0","endTime":"0","summary":"金吾财讯 | 申万宏源发布研报指，首次覆盖海西新药 ，给予“买入”评级，目标价298.28港元。研报指出，海西新药是一家通过仿制药业务已连续5年实现盈利的创新药企业，2025年营业收入达到5.82亿元人民币，同比增长25%，净利润达1.77亿元，同比增长30%。在仿制药业务稳定盈利后，公司大力推进创新药研发。首发适应症骨肉瘤预计2026年上半年开展III期临床研究。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000166","159992","02637","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU0455707207.USD","159992","HK0000165453.HKD","09969","BK1583","LU2097828805.USD","06855","LU2328871848.SGD","LU0502904849.HKD","LU2242644610.SGD","01477","LU2097828474.EUR","LU0196878994.USD","02637","BK1515","LU2097828557.USD","LU2488822045.USD","01672","LU2097828714.EUR","BK1589","BK1574","LU2097828631.EUR","01801","BK1161","LU1969619763.USD","06990","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629089539","title":"港股异动 | 海西新药(02637)涨超7%破顶 HXP056有望迎来数据验证 药品具全球重磅大单品潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2629089539","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629089539?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:26","pubTimestamp":1776997619,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超7%，盘中高见230.4港元创新高。消息面上，近期，海西新药公告新一代原创创新药项目HXP056口服治疗眼底病的最新进展。申万宏源指出，HXP056 I期临床数据显示，该药物具备良好安全性与耐受性，在wAMD初治或经治患者中，均可观察到眼底形态与视网膜功能有初步改善。在稳定且持续盈利后，公司大力推进创新药研发，进度最快的C019199即将进入III期临床阶段，具有全球重磅大单品潜力的HXP056有望迎来数据验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02637","BK4585","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628741229","title":"港股异动 | 海西新药(02637)涨超4% HXP056显著抑制眼底渗漏 后续成功上市有望改写wAMD治疗格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2628741229","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628741229?lang=zh_cn&edition=full","pubTime":"2026-04-17 10:54","pubTimestamp":1776394447,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超4%，截至发稿，涨3.8%，报196.6港元，成交额2886.43万港元。HXP056有望成为全球首款治疗视网膜疾病的口服药物，这不仅代表重大技术突破，更蕴含爆发性的全球市场潜力。该行指出，临床前数据显示，海西新药HXP056显著抑制眼底渗漏，I期临床试验的wAMD初治或经治患者中均可观察到眼底形态与视网膜功能有初步改善，II期已于25Q4开展，若后续成功上市则有望改写wAMD治疗格局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02637","BK1191","IPOS","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626903801","title":"海西新药(02637)午后升幅扩至8.85%创新高 去年营收净利双增","url":"https://stock-news.laohu8.com/highlight/detail?id=2626903801","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626903801?lang=zh_cn&edition=full","pubTime":"2026-04-09 13:17","pubTimestamp":1775711834,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海西新药(02637)午后延续早盘涨势，截至发稿，上涨8.85%，报每股205.4港元，创历史新高，成交额1.1亿港元。消息面上，此前，海西新药公布2025年业绩，净利约1.77亿元，同比增长30.09%；每股盈利为2.55元。期内收益为约5.82亿元，同比增长24.79%。华源证券指出，眼底病市场空间增长且现有疗法存在痛点。而海西新药围绕眼底病布局口服小分子药物HXP056，拟覆盖wAMD、DME及RVO等适应症，临床前研究显示其能够穿透血眼屏障并在眼球实现较高分布、系统暴露较低，且已于2025年6月开展临床I期实验，具备从给药方式上重塑眼底病治疗体验的潜力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978495","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194924469","title":"海西新药3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1194924469","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194924469?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:49","pubTimestamp":1775638164,"startTime":"0","endTime":"0","summary":"2026年4月8日，海西新药发布3月证券变动月报表。报告期为2026年3月1日至3月31日。公告显示，截至3月31日，公司普通股注册股本78,707,270股，面值为每股人民币1元，注册股本总额78,707,270元，较上月无任何增减变动。已发行股份同样维持在78,707,270股，未出现新增发行、购回或注销股份的情况。报告期内，公司无新授、行使或失效的股份期权及股权激励计划，也无其他与股份发行相关的协议或安排。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955","LU1969619763.USD","BK1583","HK0000165453.HKD","159992","02162","02637","BK1587","02157","BK1574","09995","LU2328871848.SGD","BK1191","06978","BK1593","06855","01477","01530","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":-0.0695},{"period":"1month","weight":0.1479},{"period":"3month","weight":0.6088},{"period":"6month","weight":0.6636},{"period":"1year","weight":1.5417},{"period":"ytd","weight":0.6147}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.041},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}